Abstract
The prevalence of antiphospholipid antibodies (aPL) in otherwise healthy populations is less than 1%. Many autoantibodies become more prevalent with increasing age and aPL is no exception. aPL has been reported in 10–20% of the healthy elderly population.
In autoimmune diseases, especially SLE, however, the prevalence is much higher. The Euro-Lupus study found a prevalence of 24% for IgG anticardiolipin antibody (aCL), 13% for IgM aCL, and 15% for lupus anticoagulant (LA), respectively, in a cohort of 1,000 patients with SLE. A recent study showed that the prevalence of antiphospholipid syndrome (APS) increases from 10 to 23% after 15–18 years in a large cohort of SLE patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine (Baltimore) 82(5):299–308
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 46(4):1019–1027
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag London
About this chapter
Cite this chapter
Bertolaccini, M.L., Ateka-Barrutia, O., Khamashta, M.A. (2010). Epidemiology. In: Antiphospholipid Syndrome Handbook. Springer, London. https://doi.org/10.1007/978-1-84628-735-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-84628-735-0_2
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84628-522-6
Online ISBN: 978-1-84628-735-0
eBook Packages: MedicineMedicine (R0)